

Express Mail No. EV 576 489 667 US 0/5

1 JAN 2005

INFORMATION DISCLOSURE STATEMENT	
Address to: Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket HANO-002
	First Named Inventor CHUNG, HESSON
	Application Number 10/521,678
	Confirmation No. 9260
	Filing Date September 2, 2005
	Group Art Unit To Be Assigned
	Examiner Name To Be Assigned
	Title: 'P-GLYCOPROTEIN INHIBITOR COMPRISING OCTILONIUM BROMIDE AS AN EFFECTIVE INGREDIENT"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. HANO-002 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 2/Aug/05

By: 

Karl Bozicevic
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/521,678
				Filing Date	September 2, 2005
				First Named Inventor	CHUNG, HESSON
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	HANO-002

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,978,772		Casini et al.	12-18-1990	
		5,968,972		Broder et al.	10-19-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
		EVANGELISTA et al., "Receptor Binding Profile of Otilonium Bromide" <i>Pharmacological Research</i> , 38(2):111-117 (1998)					
		GANDIA et al., "Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells" <i>British Journal of Pharmacology</i> , 117:463-470 (1996)					
		POYNARD et al., "Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome" <i>Aliment Pharmacol Ther.</i> 15:355-361 (2001)					
		SANTICOLI et al., "Antimuscarinic, calcium channel blocker and tachykinin NK ₂ receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon" <i>Nauyn-Schmiedeberg's Arch Pharmacol</i> 359:420-427 (1999)					

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.